Lance Willsey Buys 50,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) Director Lance Willsey bought 50,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the purchase, the director directly owned 1,291,780 shares in the company, valued at $6,135,955. This represents a 4.03% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

FocalTherics Stock Performance

NASDAQ:FOCL opened at $4.76 on Monday. The company has a market capitalization of $178.40 million, a PE ratio of -4.62 and a beta of -0.04. The stock has a fifty day simple moving average of $5.39. FocalTherics has a 1 year low of $1.30 and a 1 year high of $6.40. The company has a debt-to-equity ratio of 1.79, a quick ratio of 0.99 and a current ratio of 1.34.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The company had revenue of $13.20 million for the quarter. On average, equities research analysts predict that FocalTherics will post -0.78 EPS for the current year.

Wall Street Analyst Weigh In

FOCL has been the topic of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and set a $4.00 price objective on shares of FocalTherics in a research note on Friday. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, FocalTherics has a consensus rating of “Hold” and an average price target of $7.75.

Hedge Funds Weigh In On FocalTherics

Several large investors have recently made changes to their positions in FOCL. SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics during the 1st quarter valued at about $38,000. Lido Advisors LLC bought a new stake in shares of FocalTherics in the 1st quarter worth approximately $40,000. Kovack Advisors Inc. acquired a new stake in FocalTherics during the fourth quarter valued at approximately $53,000. Leonteq Securities AG acquired a new stake in FocalTherics during the fourth quarter valued at approximately $313,000. Finally, Flax Pond Capital LLC bought a new stake in FocalTherics during the fourth quarter worth approximately $2,623,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.